Premium
STEROIDOGENESIS IN A VIRILIZING OVARIAN TUMOUR
Author(s) -
MASCHLER I.,
WEIDENFELD J.,
FLEISCHER B.,
EHRENFELD E. N.,
FINKELSTEIN M.
Publication year - 1975
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1975.tb01550.x
Subject(s) - medicine , endocrinology , ovary , biology
SUMMARY A metabolic study with tissue from a virilizing arrhenoblastoma, using as precursors [7‐ 3 H]pregnenolone, [7‐ 3 H]17α‐hydroxypregnenolone, [4‐ 14 C]17α‐hydroxy‐progesterone and [4‐ 14 C]testosterone, revealed that in spite of a deficient activity of 3β‐hydroxysteroid dehydrogenase‐5‐isomerase the overall production of test‐osterone was compensated by an increased activity of a lyase converting[4‐ 14 C]17α‐hydroxyprogesterone to testosterone (via androstenedione) and was comparable to the production obtained by normal ovarian tissue. The masculinizing effects of the tumour in vivo were most probably caused by accumulation of testosterone due to deficiencies in enzymes catabolizing testosterone to 17‐ketosteroids and its aromatization to oestrogen. The unique property of the arrhenoblastoma to convert [4‐ 14 C]17α‐hydroxyprogesterone to [4‐ 14 C]11‐deoxycortisol (Reichstein's compound S) suggests an adrenal origin of the tumour which may explain its limited capacity to aromatize testosterone.